While main results from a platform study of four experimental drugs for amyotrophic lateral sclerosis are negative, it shows ...
Massachusetts General Hospital coordinated the first four platform trials within the HEALEY ALS platform to evaluate ...
GlobalData on MSN6d
Four regimens fail endpoints simultaneously in HEALEY ALS trialALS candidates from Biohaven, Prilenia, Clene and UCB have all failed to halt disease progression versus placebo in the ...
NEW research has shown that pridopidine, a sigma-1 receptor agonist, does not exhibit a significant impact on the progression of amyotrophic lateral sclerosis (ALS) over a 24-week period.
Longitudinal ALS patient data from APST Research will enable a more robust analysis of the effect of CNM-Au8 on NfL biomarkers; APST Research data includes thousands of people liv ...
A new study published in the recent issue of Journal of American Medical Association found that the usage of verdiperstat, a ...
Of the first four experimental ALS treatments tested in the HEALEY platform trial, CNM-Au8 and pridopridine showed some ...
Denali Therapeutics' experimental drug for amyotrophic lateral sclerosis (ALS) failed to show efficacy in part of the phase 2/3 HEALEY ALS basket trial, causing a fall in its share price.
So, this is four trials, all undertaken within what's called the HEALEY ALS Platform. Let me first say these studies looked at four different agents to treat ALS, a fatal neurodegenerative disorder.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback